DE602007006525D1 - 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung - Google Patents

2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung

Info

Publication number
DE602007006525D1
DE602007006525D1 DE602007006525T DE602007006525T DE602007006525D1 DE 602007006525 D1 DE602007006525 D1 DE 602007006525D1 DE 602007006525 T DE602007006525 T DE 602007006525T DE 602007006525 T DE602007006525 T DE 602007006525T DE 602007006525 D1 DE602007006525 D1 DE 602007006525D1
Authority
DE
Germany
Prior art keywords
atpyridine
aryl
derivatives
preparation
therapeutic use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007006525T
Other languages
English (en)
Inventor
Garcia Antonio Almario
Patrick Lardenois
Anne Olivier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of DE602007006525D1 publication Critical patent/DE602007006525D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602007006525T 2006-09-22 2007-09-19 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung Active DE602007006525D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0608350A FR2906250B1 (fr) 2006-09-22 2006-09-22 Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
PCT/FR2007/001517 WO2008034974A1 (fr) 2006-09-22 2007-09-19 DERIVES DE 2-ARYL-6-PHENYL-IMIDAZO[1,2-α]PYRIDINES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Publications (1)

Publication Number Publication Date
DE602007006525D1 true DE602007006525D1 (de) 2010-06-24

Family

ID=37841968

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007006525T Active DE602007006525D1 (de) 2006-09-22 2007-09-19 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung

Country Status (44)

Country Link
US (1) US7915284B2 (de)
EP (1) EP2069342B1 (de)
JP (1) JP5336378B2 (de)
KR (1) KR101470039B1 (de)
CN (1) CN101516881B (de)
AR (1) AR062897A1 (de)
AT (1) ATE467633T1 (de)
AU (1) AU2007298856B2 (de)
BR (1) BRPI0718517A2 (de)
CA (1) CA2662848C (de)
CL (1) CL2007002733A1 (de)
CO (1) CO6160308A2 (de)
CR (1) CR10643A (de)
CY (1) CY1110232T1 (de)
DE (1) DE602007006525D1 (de)
DK (1) DK2069342T3 (de)
EA (1) EA017442B1 (de)
ES (1) ES2345016T3 (de)
FR (1) FR2906250B1 (de)
GT (1) GT200900049A (de)
HK (1) HK1135388A1 (de)
HN (1) HN2009000502A (de)
HR (1) HRP20100408T1 (de)
IL (1) IL197352A (de)
JO (1) JO2643B1 (de)
MA (1) MA30792B1 (de)
ME (1) MEP10709A (de)
MX (1) MX2009002802A (de)
MY (1) MY145603A (de)
NI (1) NI200900037A (de)
NO (1) NO20091562L (de)
NZ (1) NZ575337A (de)
PE (1) PE20080671A1 (de)
PL (1) PL2069342T3 (de)
PT (1) PT2069342E (de)
RS (1) RS51412B (de)
SI (1) SI2069342T1 (de)
SV (1) SV2009003193A (de)
TN (1) TN2009000081A1 (de)
TW (1) TWI381837B (de)
UA (1) UA95976C2 (de)
UY (1) UY30603A1 (de)
WO (1) WO2008034974A1 (de)
ZA (1) ZA200901551B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2928921B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique
FR2928924B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
FR2928922B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
FR2933609B1 (fr) 2008-07-10 2010-08-27 Fournier Lab Sa Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
FR2950345B1 (fr) * 2009-09-18 2011-09-23 Sanofi Aventis Derives acetyleniques de 5-phenyl-pyrazolopyridine, leur preparation et leur application en therapeutique
FR2950344B1 (fr) * 2009-09-18 2011-11-25 Sanofi Aventis Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique.
FR2953520B1 (fr) * 2009-12-04 2011-11-25 Sanofi Aventis Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
KR101735975B1 (ko) * 2012-11-29 2017-05-15 에프. 호프만-라 로슈 아게 이미다조피리딘 유도체
EP3070085B1 (de) 2013-02-04 2019-01-09 Janssen Pharmaceutica NV Flap-modulatoren
TWI644899B (zh) 2013-02-04 2018-12-21 健生藥品公司 Ｆｌａｐ調節劑
EP3027615B1 (de) * 2013-08-02 2021-07-21 Institut Pasteur Korea Antiinfektionsverbindungen
KR20170137165A (ko) 2015-04-10 2017-12-12 베이진 엘티디 인돌아민 및/또는 트립토판 2,3-디옥시게나아제로서 신규한 5 또는 8-치환된 이미다조[1,5-a]피리딘
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
CA3005727A1 (en) 2015-11-19 2017-05-26 Incyte Corporation Substituted 2-methylbiphenyl-3-yl heterocyclic compounds and pharmaceutical compositions thereof useful as immunomodulators
PE20230731A1 (es) 2015-12-22 2023-05-03 Incyte Corp Compuestos heterociclicos como inmunomoduladores
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
PE20190731A1 (es) 2016-06-20 2019-05-23 Incyte Corp Compuestos heterociclicos como inmunomoduladores
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
EP3515914A4 (de) 2016-09-24 2020-04-15 BeiGene, Ltd. Neuartige 5- oder 8-substituierte imidazo[1,5-a]pyridine als selektive inhibitoren von indoleamin- und/oder tryptophan-2,3-dioxygenasen
EP3558989B1 (de) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridin-derivate als immunmodulatoren
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
MY197635A (en) 2016-12-22 2023-06-29 Incyte Corp Benzooxazole derivatives as immunomodulators
BR112019012957A2 (pt) 2016-12-22 2019-11-26 Incyte Corp derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1
US11472788B2 (en) 2017-11-25 2022-10-18 Beigene, Ltd. Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases
HRP20230090T1 (hr) 2018-03-30 2023-03-17 Incyte Corporation Heterociklički spojevi kao imunomodulatori
CN112752756A (zh) 2018-05-11 2021-05-04 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
PE20230407A1 (es) 2019-11-11 2023-03-07 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
MX2023005362A (es) 2020-11-06 2023-06-22 Incyte Corp Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4041624B2 (ja) * 1999-07-21 2008-01-30 三井化学株式会社 有機電界発光素子
US6489337B1 (en) * 2000-03-31 2002-12-03 Ortho-Mcneil Pharmaceutical, Inc. Method for treating histamine H3 receptor-mediated disorders with 2- or 3-aryl substituted imidazo[1,2-a] pyridines
GB0119911D0 (en) * 2001-08-15 2001-10-10 Novartis Ag Organic Compounds
CN100549011C (zh) * 2002-09-19 2009-10-14 先灵公司 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
JP2007527908A (ja) * 2004-03-08 2007-10-04 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 抗原虫薬としての新規ジカチオン性イミダゾ［１，２−ａ］ピリジン、及び５，６，７，８−テトラヒドロ−イミダゾ［１，２−ａ］ピリジン

Also Published As

Publication number Publication date
EA200970311A1 (ru) 2009-08-28
CO6160308A2 (es) 2010-05-20
ES2345016T3 (es) 2010-09-13
PT2069342E (pt) 2010-07-19
NZ575337A (en) 2011-12-22
BRPI0718517A2 (pt) 2013-11-19
AU2007298856B2 (en) 2012-08-09
AU2007298856A1 (en) 2008-03-27
WO2008034974A1 (fr) 2008-03-27
MA30792B1 (fr) 2009-10-01
US20090253735A1 (en) 2009-10-08
EA017442B1 (ru) 2012-12-28
UA95976C2 (en) 2011-09-26
CL2007002733A1 (es) 2008-04-11
KR20090054449A (ko) 2009-05-29
CY1110232T1 (el) 2015-01-14
EP2069342B1 (de) 2010-05-12
PE20080671A1 (es) 2008-07-14
JO2643B1 (en) 2012-06-17
MY145603A (en) 2012-03-15
CR10643A (es) 2009-04-29
PL2069342T3 (pl) 2010-10-29
TW200833329A (en) 2008-08-16
RS51412B (en) 2011-02-28
HRP20100408T1 (hr) 2010-09-30
EP2069342A1 (de) 2009-06-17
ME00615B (me) 2011-12-20
TWI381837B (zh) 2013-01-11
SV2009003193A (es) 2010-02-01
NI200900037A (es) 2014-02-20
IL197352A0 (en) 2009-12-24
CA2662848C (fr) 2014-12-23
UY30603A1 (es) 2008-05-02
MX2009002802A (es) 2009-04-01
HK1135388A1 (de) 2010-06-04
HN2009000502A (es) 2011-07-11
CA2662848A1 (fr) 2008-03-27
CN101516881A (zh) 2009-08-26
JP2010504309A (ja) 2010-02-12
CN101516881B (zh) 2012-07-18
AR062897A1 (es) 2008-12-10
JP5336378B2 (ja) 2013-11-06
US7915284B2 (en) 2011-03-29
IL197352A (en) 2014-11-30
ATE467633T1 (de) 2010-05-15
KR101470039B1 (ko) 2014-12-05
DK2069342T3 (da) 2010-08-23
NO20091562L (no) 2009-04-20
MEP10709A (en) 2011-12-20
FR2906250B1 (fr) 2008-10-31
ZA200901551B (en) 2010-06-30
SI2069342T1 (sl) 2010-09-30
FR2906250A1 (fr) 2008-03-28
TN2009000081A1 (en) 2010-08-19
GT200900049A (es) 2010-03-04

Similar Documents

Publication Publication Date Title
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
ATE395342T1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
ATE459608T1 (de) Oxopiperidinderivate, ihre herstellung und therapeutische verwendung
DE602005002470D1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
DE502005002105D1 (de) 4-benzimidazol-2-yl-pyridazin-3-on-derivative, ihre herstellung und verwendung in arzneimitteln
ATE543808T1 (de) 5,6-ring-annelierte indolderivate und ihre verwendung
DK2049525T3 (da) N-laminoheteroaryl)-1H-indol-2-carboxamid-derivater, og fremstilling og terapeutisk anvendelse deraf
ATE461930T1 (de) Harnstoffderivate von tropan, ihre herstellung und ihre therapeutische anwendung
ATE512970T1 (de) Dimere von artemisininderivaten, deren herstellung und deren therapeutische verwendung
ATE451923T1 (de) N-(arylalkyl)-1h-pyrrolopyridin-2-carboxamid- derivate, ihre herstellung und verwendung
ATE420081T1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
ATE417846T1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung
ATE540023T1 (de) Neuartige 3-aminoalkyl-1,3-dihydro-2h-indol-2-on- derivate, ihre herstellung und therapeutische verwendung
ATE542806T1 (de) Diarylmethylpiperazinderivate, deren herstellung und deren verwendung
ATE475661T1 (de) Triazolopyridin-carboxamid-derivate sowie ihre herstellung und therapeutische verwendung
ATE474840T1 (de) 6-heteroarylpyridoindolon-derivate, ihre herstellung und ihre therapeutische anwendung
ATE520654T1 (de) Polypyrrol-derivate, ihre herstellung und ihre therapeutische verwendung
ATE499351T1 (de) Aryl- und heteroaryl-ethyl-acylguanidinderivate, ihre herstellung und ihre therapeutische anwendung
ATE411295T1 (de) 2h- oder 3h-benzoäeüindazol-1-yl-karbamat- derivate, herstellung und therapeutische verwendung
DE602006007702D1 (de) Polymernitroxide sowie ihre herstellung und verwendung
ATE549339T1 (de) Derivate von pyrrolopyridin-2-carboxamiden, ihre herstellung und ihre therapeutische anwendung
DK2118104T3 (da) Azabicycloalkanderivater, fremstilling og terapeutisk anvendelse heraf
DE602006008971D1 (de) N-ä(4,5-diphenylpyrimidin-2-yl)methylüaminderivate, deren herstellung und deren therapeutische verwendung
IL191892A0 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition